Every material Form 8-K Vir Biotechnology has filed with the SEC since May 07, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vir Biotechnology said its pivotal Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart in adults with chronic hepatitis delta met its primary and key secondary endpoints, with data presented at the AASLD Liver Meeting on November 8, 2026. The company also released expanded Phase 2 SOLSTICE data and preliminary, exploratory findings on treatment discontinuation, which the company itself says are interim and not a complete assessment of safety or efficacy.
ECLIPSE 1 primary endpoint: 44% of patients on elebsiran and tobevibart reached undetectable virus plus ALT normalization at Week 48, versus 0% in the delayed treatment group at Week 12 (p<0.0001)
Key secondary endpoint: 79% reached undetectable virus at Week 48, versus 0% in the delayed treatment group
SOLSTICE Week 96: 100% (28/28) of patients who completed Week 96 of combination therapy reached undetectable viremia
Exploratory analysis: 10 patients discontinued treatment; all 10 achieved SVR12, with 7 reaching SVR24 and 1 reaching SVR48; the filing states these data are preliminary and not a claim of cure
Vir Biotechnology reported third quarter 2026 results with a net loss of $96.3 million, or $0.57 per share, compared with $163.1 million, or $1.17 per share, a year earlier. The prior-year period included a non-recurring $75.0 million milestone expense, and total revenues were a loss of $188 thousand versus $240 thousand of revenue in the prior year. The company also reported topline Phase 3 ECLIPSE 1 data for hepatitis delta expected in the fourth quarter of 2026, and said its cash runway extends into the second half of 2028.
Net loss was $96.3 million, or $0.57 per share, versus $163.1 million, or $1.17 per share, in Q3 2025
R&D expenses were $80.0 million versus $151.5 million a year earlier, which included a $75.0 million milestone expense
Cash, cash equivalents and investments were $901.3 million at September 30, 2026, down $106.5 million in the quarter
Topline ECLIPSE 1 Phase 3 data expected in Q4 2026; company expects cash to fund operations into the second half of 2028
Vir Biotechnology's Board increased its size from eight to nine members and appointed Suzanne Topalian, M.D., to fill the new seat, effective October 27, 2026. She also joined the Science and Technology Committee and receives the standard non-employee director compensation, including automatic option and restricted stock unit grants.
Board expanded from eight to nine members; Dr. Topalian named Class III director through the 2028 annual meeting
Dr. Topalian appointed to the Science and Technology Committee, effective October 27, 2026
She received stock option and restricted stock unit awards under the 2019 Equity Incentive Plan on her appointment date
Company has signed its standard indemnity agreement with Dr. Topalian
Vir Biotechnology appointed Aziz Sawaf, formerly CFO of Theravance Biopharma, as Executive Vice President and Chief Financial Officer, effective October 5, 2026. Brent Sabatini, who has been interim principal financial officer, will stop serving in that role and remain Senior Vice President and Chief Accounting Officer.
Sawaf's annualized base salary is $520,000, with a target bonus of 45% of base salary and a one-time cash sign-on bonus of $150,000.
Sawaf's offer includes an option to buy 150,000 shares and 75,000 restricted stock units, granted on or around November 15, 2026.
Under the Severance Plan, a covered termination after a change in control yields a lump sum of 12 months' base salary plus target bonus, while one outside that period yields nine months' base salary plus a pro-rated bonus.
Vir Biotechnology reported second quarter 2026 net income of $80.1 million, or $0.47 per diluted share, versus a net loss of $111.0 million a year earlier, driven by $238.9 million of license and collaboration revenue tied to the closed Astellas collaboration. Cash, cash equivalents and investments were about $1.01 billion at June 30, 2026, and the company expects that cash to fund operations into the second half of 2028.
Total revenues were $238.9 million in the quarter, versus $1.2 million a year earlier, mainly from the $240.0 million Astellas upfront payment.
Research and development expenses rose to $135.3 million from $97.5 million, including a $48.0 million milestone payment to Sanofi.
Cash, cash equivalents and investments were about $1.01 billion at June 30, 2026, up about $198.5 million in the quarter.
Topline data from Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.
Vir Biotechnology's Chief Financial Officer, Jason O'Byrne, will step down effective August 3, 2026 to pursue another opportunity, and the company says his departure was not due to any disagreement on its operations, policies, or practices. The board has named Brent Sabatini, the company's Chief Accounting Officer, as interim principal financial officer effective the same date while Vir searches for a successor, a change that matters to shareholders because it concerns who leads financial reporting during the transition.
Jason O'Byrne, Executive Vice President and Chief Financial Officer, informed Vir on July 20, 2026 that he will step down effective August 3, 2026.
The board appointed Brent Sabatini, Senior Vice President and Chief Accounting Officer, as interim principal financial officer on July 23, 2026, effective August 3, 2026.
Sabatini has served as Chief Accounting Officer since February 2023 and as principal accounting officer since October 2024; he will receive no added compensation for the interim role.
Vir has initiated a search for O'Byrne's successor; the filing gives no timeline for that search.
Vir Biotechnology expanded its board from seven to eight members on June 9, 2026, and appointed Timothy Coughlin, CPA, to the new seat and as Chair of the Audit Committee, effective immediately. The change adds a new director to oversee financial reporting and audit matters, and the filing discloses no related party transactions involving him.
Board size increased from seven to eight members; Timothy Coughlin, CPA, appointed as Class III director until the 2028 annual meeting
Coughlin named Chair of the Audit Committee, effective immediately
As a non-employee director, he receives standard compensation under the company's director policy and automatic option and RSU grants on his appointment date
Company has entered into its standard indemnity agreement with him
Saira Ramasastry left Vir Biotechnology's Board and Audit Committee effective May 26, 2026, citing a business conflict and stating her decision was not due to any disagreement with the Company. The Board named Robert More as Audit Committee chair and reduced its size from eight to seven members, and at the May 26, 2026 Annual Meeting stockholders elected three Class I directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as auditor for 2026.
Saira Ramasastry stepped down from the Board and the Audit Committee effective May 26, 2026, citing a business conflict.
Robert More, MBA, was appointed Audit Committee chair, and the Board size was reduced from eight to seven members, both effective upon Ramasastry's departure.
At the May 26, 2026 Annual Meeting, Robert More, Janet Napolitano, J.D., and Elliott Sigal, M.D., Ph.D., were elected Class I directors to serve until the 2029 annual meeting.
Stockholders approved executive compensation on an advisory basis with 108,453,963 votes for and 11,863,405 against, and ratified Ernst & Young LLP for fiscal 2026 with 137,048,756 votes for.
Vir Biotechnology reported a first-quarter 2026 net loss of $125.7 million, or $0.85 per share, compared with a net loss of $121.0 million, or $0.88 per share, a year earlier. Total revenues were negative $29 thousand, down from $3.0 million, while R&D and SG&A expenses both declined. The company said its cash, cash equivalents and investments were $809.3 million at March 31, 2026, and expects them to fund operations into the second half of 2028.
Net loss was $125.7 million ($0.85 per share) for Q1 2026, versus $121.0 million ($0.88 per share) in Q1 2025.
Total revenues were negative $29 thousand in Q1 2026, compared with $3.0 million in Q1 2025.
R&D expenses fell to $108.9 million from $118.6 million, mainly due to a $30.0 million expense in Q1 2025 tied to the restated Alnylam agreement.
The Astellas collaboration on VIR-5500 closed in April, with a combined upfront payment and equity investment of $315 million expected in Q2 2026.
Vir Biotechnology said its Executive Vice President and Chief Medical Officer, Mark Eisner, informed the company on April 7, 2026 that he will step down effective April 24, 2026. The company has started searching for a successor, and the filing does not name an interim replacement.
Mark Eisner, EVP and Chief Medical Officer, will step down effective April 24, 2026.
He informed the company of his decision on April 7, 2026.
On March 4, 2026, Vir Biotechnology's board appointed Chief Executive Officer Marianne De Backer to the additional position of President. The filing describes no change to her compensation and no financial results, so the change is administrative in nature and reflects a broader role for the chief executive.
Marianne De Backer, Ph.D., remains Chief Executive Officer and principal executive officer and adds the title of President.
Board of Directors made the appointment on March 4, 2026.
Filing states no family relationship and no related-party transactions requiring disclosure for Dr. De Backer.
Biographical details are incorporated by reference from the proxy statement filed April 17, 2025.
Vir Biotechnology entered into an underwriting agreement on February 25, 2026, to sell 17,647,059 shares of common stock at $8.50 per share. The company expects net proceeds of about $141.1 million, or about $162.3 million if underwriters fully exercise their option for additional shares, but the sale adds new shares outstanding, which dilutes existing shareholders.
Offering of 17,647,059 common shares at $8.50 per share, with underwriters led by Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc.
Expected net proceeds of approximately $141.1 million, or approximately $162.3 million if the underwriters' option is fully exercised.
Underwriters hold a 30-day option to buy up to 2,647,058 additional shares at the public offering price.
Offering is expected to close on February 27, 2026, subject to customary closing conditions.
Vir Biotechnology agreed with Astellas on a global collaboration to co-develop and co-commercialize VIR-5500, a Phase 1 prostate cancer candidate, with closing subject to U.S. antitrust clearance. The same day, the company reported 2025 results: full-year revenue fell to $68.6 million while the full-year net loss narrowed to $438.0 million.
Vir to receive $335 million in upfront and near-term milestone payments, including $240 million in cash, a $75 million equity investment and a $20 million milestone
Astellas agreed to buy 7,239,382 shares at $10.36 per share, a 50% premium to the 30-day volume weighted average price as of February 17, 2026
Vir is eligible for up to $1.37 billion in future milestones; U.S. profit and loss are shared equally and Vir holds a U.S. co-promotion option
Full-year 2025 revenue was $68.6 million versus $74.2 million in 2024; full-year net loss was $438.0 million, or $(3.16) per share, versus $522.0 million, or $(3.83) per share
Vir Biotechnology said it had approximately $781 million in cash, cash equivalents and investments as of December 31, 2025, an unaudited figure, and that this balance is expected to fund operations into the fourth quarter of 2027, which it links to the Norgine licensing agreement and continued financial discipline. It also released updated Phase 2 SOLSTICE data for its chronic hepatitis delta combination therapy, with 88% of participants evaluated through Week 96 reaching undetectable hepatitis delta virus RNA versus 46% on the antibody alone. The filing contains no full-year revenue or profit figures, which the company expects to report in late February 2026.
Preliminary, unaudited cash, cash equivalents and investments of approximately $781 million as of December 31, 2025; full fourth-quarter and 2025 results expected in late February 2026.
Cash runway extended into the fourth quarter of 2027, tied by the company to the Norgine license for chronic hepatitis delta in Europe, Australia and New Zealand.
SOLSTICE Phase 2: undetectable HDV RNA at Week 96 in 88% (21/24) of combination participants versus 46% (11/24) on tobevibart alone.
Company to present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. PT.
Vir Biotechnology granted Norgine Pharma UK Limited an exclusive license for commercial rights to its tobevibart and elebsiran combination for chronic hepatitis delta in Europe, Australia and New Zealand. Vir will receive an initial reimbursement of EUR 55 million, is eligible for up to EUR 495 million in milestones, and will earn royalties on net sales in that territory, while the companies share ECLIPSE trial costs. The company says the agreement extends its current cash runway into the fourth quarter of 2027.
Initial reimbursement payment of EUR 55 million to Vir, with closing for certain non-US jurisdictions subject to regulatory approval
Eligible for up to EUR 495 million in clinical, regulatory and sales milestones, plus tiered mid-teen to high-twenties percent royalties on net sales in the licensed territory
Norgine to contribute approximately 25% of go-forward external costs for the ECLIPSE 1, 2 and 3 trials
Vir retains commercial rights in the United States and other markets outside the Greater China Territory; company expects cash runway into Q4 2027
Vir Biotechnology reported third quarter 2025 results for the period ended September 30, 2025. Net loss narrowed to $163.1 million, or $1.17 per share, from $213.7 million, or $1.56 per share, a year earlier, mainly because license expenses were lower than in the prior-year quarter, but total revenues fell to $0.2 million from $2.4 million. The company said it had $810.7 million in cash, cash equivalents and investments and expects that to fund operations into mid-2027.
Net loss was $163.1 million, or $1.17 per share, versus $213.7 million, or $1.56 per share, in Q3 2024
Total revenues were $0.2 million versus $2.4 million in Q3 2024; R&D expenses were $151.5 million versus $195.2 million
Cash, cash equivalents and investments were $810.7 million at September 30, 2025, down about $81.4 million in the quarter; ECLIPSE 1 Phase 3 enrollment completed about two months early
Vir Biotechnology reported second-quarter 2025 results, with a net loss of $111.0 million, or $0.80 per share, compared with $138.4 million, or $1.02 per share, a year earlier. Revenue fell to $1.2 million from $3.1 million, and cash, cash equivalents and investments were $892.1 million at June 30, 2025, which the company says funds operations into mid-2027.
Net loss was $111.0 million ($0.80 per share) versus $138.4 million ($1.02 per share) in Q2 2024.
Total revenues were $1.2 million versus $3.1 million in Q2 2024.
Cash, cash equivalents and investments were $892.1 million at June 30, 2025, down about $127.7 million in the quarter, including $50.5 million of ECLIPSE milestone payments.
R&D expenses were $97.5 million versus $105.1 million, reflecting restructuring savings; the ECLIPSE registrational program in chronic hepatitis delta is fully underway.
Vir Biotechnology reported first quarter 2025 results, with total revenue of $3.0 million, down from $56.4 million a year earlier, mainly because $51.7 million of deferred revenue was recognized in Q1 2024. The net loss grew to $121.0 million, or $(0.88) per share, from $65.3 million, or $(0.48) per share, as research and development spending rose to $118.6 million. The company said its roughly $1.0 billion in cash and investments funds operations into mid-2027.
Total revenue was $3.0 million for Q1 2025, versus $56.4 million for Q1 2024.
Net loss was $121.0 million, or $(0.88) per share, versus $65.3 million, or $(0.48) per share, a year earlier.
R&D expense rose to $118.6 million, including a $30.0 million expense to Alnylam and the start of the ECLIPSE Phase 3 program.
Cash, cash equivalents and investments were approximately $1.02 billion at March 31, 2025, down about $75.6 million in the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vir Biotechnology filing is on SEC EDGAR ↗. 8-K briefs of other companies →